Figure 3: Overall survival (OS) and progression-free survival (PFS) for absolute lymphocyte count at day 15 (ALC-15); absolute monocyte count at day 15 (AMC-15); and absolute lymphocyte count/absolute monocyte count ratio at day 15 (ALC/AMC-15) post-autologous peripheral hematopoietic stem cell transplantation (APHSCT). The median OS (3a) and PFS (3b) times for ALC-15 = 500 cells/Ál vs < 500 cells/Ál were not reached vs 11.4 months, 5-year OS rates of 72% vs 28%; and 197.0 months vs 5.8 months, 5-year PFS rates of 66% vs 24%, respectively. The median OS (3c) and PFS (3d) times for AMC-15 = 600 cells/Ál vs < 600 cells/Ál were 15.3 months vs not reached , 5-year OS rates of 27% vs 74%; and 6.0 months vs 142.0 months, 5-year PFS rates of 24% vs 68%, respectively. The median OS (3e) and PFS (3f) times for ALC/AMC-15 = 1 vs < 1 were not reached vs 9.9 months, 5-year OS rates of 86% vs 16%; and 197.0 months vs 4.4 months, 5-year PFS rates of 83% vs 10%, respectively.